Use of recombinant factor VIIA for control of combat-related haemorrhage

Emergency Medicine Journal

Volumn 27, Issue 2, 2010, Pages 121-124

  Woodruff, Susan I ^a   Dougherty, Amber L ^b   Dye, Judy L ^b   Mohrle, Charlene R ^b   Galarneau, Michael R ^c  

^a SAN DIEGO STATE UNIVERSITY   (United States)

^b SCIENCE APPLICATIONS INTERNATIONAL CORPORATION   (United States)

^c NAVAL MEDICAL CENTER SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ABDOMINAL PENETRATING TRAUMA; ADULT; ARMY; ARTICLE; BATTLE INJURY; BLEEDING; BLOOD; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOPRECIPITATE; ERYTHROCYTE CONCENTRATE; GUNSHOT INJURY; HUMAN; INJURY SEVERITY; IRAQ; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PENETRATING TRAUMA; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SHOCK;

ADULT; CRANIOCEREBRAL TRAUMA; FACTOR VIIA; HEMORRHAGE; HEMOSTATICS; HUMANS; MALE; MILITARY PERSONNEL; RECOMBINANT PROTEINS; WOUNDS, PENETRATING; YOUNG ADULT;

EID: 76749149004     PISSN: 14720205     EISSN: 14720213     Source Type: Journal    
DOI: 10.1136/emj.2008.060657     Document Type: Article

References (28)

1. Life Sciences Research Office (LSRO). Armed forces search for ways to improve survival in the combat zone 2005 July. http://www.lsro.org/articles/ resusc-press-release.html (accessed 7 Sep 2006).
2. Bellamy RF. The causes of death in conventional land warfare: implications for combat casualty care research. Mil Med 1984;149:55-62.
3. Carey ME. Analysis of wounds incurred by US Army Seventh Corps personnel treated in Corps hospital during Operation Desert Storm, Feb 20 to Mar 10, 1991. J Trauma 1996;40(Suppl):S165-9.
4. Holcomb JB. Treatment of an acquired coagulopathy and recombinant activated factor VII in a damage-control patient. Mil Med 2005;170:287-90.
5. Boffard KD, Riou B, Warren B, et al. Recombinant Factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005; 59:8-17.
6. Hedner U, Erhardtsen E. Potential role for RFVIIa in transfusion medicine. Transfusion 2002;42:114-24.
7. Sapsford W. The potential use of recombinant activated Factor VII in trauma and surgery. Scand J Surg 2004;93:17-23.
8. O'Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006;295:293-8.
9. Benharash P, Bongard F, Putnam B. Use of recombinant Factor VIIa for adjunctive hemorrhage control in trauma and surgical patients. Am Surg 2005;71:776-80.
10. Spinella PC, Perkins JG, Laughlin DF, et al. The effect of recombinant activated factor VII on mortality in combat-related casualties with severe trauma and massive transfusion. J Trauma 2008;64:286-94.
11. Perkins JG, Schreiber MA, Wade CE, et al. Early versus late recombinant factor VIIA in combat trauma patients requiring massive transfusion. J Trauma 2007;62:1099-101.
12. Galarneau MR, Hancock WC, Konoske P, et al. The navy-marine corps combat trauma registry. Mil Med 2006;171:691-7.
13. Kluger Y, Riou B, Rossaint R, et al. Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial. Crit Care 2007;11:R85.
14. Baker SP, O'Neil B, Haddon W, et al. The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma 1974;14:187-96.
15. Baker SP, O'Neil B. The injury severity score: an update. J Trauma 1976;16:882-5.
16. Manning JE. Fluid and blood resuscitation. In:Tintinalli JE, Kelen GD, Stapczynski JS, eds. Emergency medicine: a comprehensive study guide. 6th edn. New York (NY): McGraw-Hill, 2004. Chapter 31, page 227.
17. O'Neill PA, Bluth M, Gloster ES, et al. Successful use of recombinant activated factor VII for trauma-associated hemorrhage in a patient without preexisting coagulopathy. J Trauma 2002;52:400-5.
18. Dutton RP, McCunn M, Hyder M, et al. Factor VIIa for correction of traumatic coagulopathy. J Trauma 2004;57:709-19.
19. Martinowitz U, Kenet G, Segal E, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2005;51:431-9.
20. Martinowitz U, Holcomb JB, Pusateri AE. Intravenous rRFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries. J Trauma 2001;50:721-9.
21. Schreiber MA, Holcomb JB, Hedner U, et al. The effect of recombinant factor VIIa on coagulopathic pigs with grade V liver injuries. J Trauma 2002;53:252-9.
22. Lynn M, Jerokhimov I, Jewelewicz D, et al. Early use of recombinant factor VIIa improves mean arterial pressure and may potentially decrease mortality in experimental hemorrhagic shock: a pilot study. J Trauma 2002;52:703-7.
23. Jeroukhimov I, Jewelewicz D, Zaias J, et al. Early injection of high-dose recombinant factor VIIa decreases blood loss and prolongs time from injury to death in experimental liver injury. J Trauma 2002;53:1053-7.
24. Duchesne JC, Mathew KA, Marr AB, et al. Current evidence based guidelines for factor VIIa use in trauma: the good, the bad, and the ugly. Am Surg 2008;74: 1159-65.
25. Rotondo MF, Zonies DH. The damage control sequence and underlying logic. Surg Clin North Am 1997;77:761-77.
26. Shapiro MB, Jenkins DH, Schwab DW, et al. Damage control: collective review. J Trauma 2000;49:969-78.
27. Kembro RJ, Horton JD, Wagner M. Use of recombinant factor VIIa in Operational Iraqi Freedom and Operation Enduring Freedom: survey of Army Surgeons. Mil Med 2008;173:1057-9.
28. Gawande A. Casualties of war - military care for the wounded from Iraq and Afghanistan. N Engl J Med 2004;351:2471-5.